Defining predictors of responsiveness to advanced therapies in Crohns disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine

Nicola J Wyatt,Hannah Watson,Carl A Anderson,Nicholas A Kennedy,Tim Raine,Tariq Ahmad,Dean Allerton,Michelle Bardgett,Emma Clark,Dawn Clewes,Cristina Cotobal Martin,Mary Doona,Jennifer A Doyle,Katherine Frith,Helen C Hancock,Ailsa L Hart,Victoria Hildreth,Peter M Irving,Sameena Iqbal,Ciara Kennedy,Andrew King,Sarah Lawrence,Charlie W Lees,Robert Lees,Laura Letchford,Trevor Liddle,James O Lindsay,Rebecca H Maier,John C Mansfield,Julian R Marchesi,Naomi McGregor,Rebecca E McIntyre,Jasmin Ostermayer,Tolulope Osunnuyi,Nick Powell,Natalie J Prescott,Jack Satsangi,Shriya Sharma,Tara Shrestha,Ally Speight,Michelle Strickland,James MS Wason,Kevin Whelan,Ruth Wood,Gregory R Young,Xinyue Zhang,Miles Parkes,Christopher J Stewart,Luke Jostins-Dean,Christopher A Lamb
DOI: https://doi.org/10.1136/bmjopen-2023-073639
IF: 3.006
2024-04-19
BMJ Open
Abstract:Introduction Characterised by chronic inflammation of the gastrointestinal tract, inflammatory bowel disease (IBD) symptoms including diarrhoea, abdominal pain and fatigue can significantly impact patient's quality of life. Therapeutic developments in the last 20 years have revolutionised treatment. However, clinical trials and real-world data show primary non-response rates up to 40%. A significant challenge is an inability to predict which treatment will benefit individual patients. Current understanding of IBD pathogenesis implicates complex interactions between host genetics and the gut microbiome. Most cohorts studying the gut microbiota to date have been underpowered, examined single treatments and produced heterogeneous results. Lack of cross-treatment comparisons and well-powered independent replication cohorts hampers the ability to infer real-world utility of predictive signatures. IBD-RESPONSE will use multi-omic data to create a predictive tool for treatment response. Future patient benefit may include development of biomarker-based treatment stratification or manipulation of intestinal microbial targets. IBD-RESPONSE and downstream studies have the potential to improve quality of life, reduce patient risk and reduce expenditure on ineffective treatments. Methods and analysis This prospective, multicentre, observational study will identify and validate a predictive model for response to advanced IBD therapies, incorporating gut microbiome, metabolome, single-cell transcriptome, human genome, dietary and clinical data. 1325 participants commencing advanced therapies will be recruited from ~40 UK sites. Data will be collected at baseline, week 14 and week 54. The primary outcome is week 14 clinical response. Secondary outcomes include clinical remission, loss of response in week 14 responders, corticosteroid-free response/remission, time to treatment escalation and change in patient-reported outcome measures. Ethics and dissemination Ethical approval was obtained from the Wales Research Ethics Committee 5 (ref: 21/WA/0228). Recruitment is ongoing. Following study completion, results will be submitted for publication in peer-reviewed journals and presented at scientific meetings. Publications will be summarised at www.ibd-response.co.uk. Trial registration number ISRCTN96296121.
medicine, general & internal
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: how to predict the responsiveness of patients with Crohn's disease (CD) and ulcerative colitis (UC) to advanced therapies in order to achieve precision medicine. Specifically, the research aims to develop a tool that can predict whether a patient will respond effectively to a specific treatment by using multi - omics data (including gut microbiome, metabolome, single - cell transcriptome, human genome, etc.), combined with clinical and dietary data. This will help to select the most suitable drugs for patients, reduce the risks and costs associated with ineffective treatment, and improve the quality of life of patients. ### Research Background Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, can cause chronic gastrointestinal inflammation and seriously affect the quality of life of patients. Although the development of biologics and other advanced therapies in recent years has significantly improved the treatment effect, up to 40% of patients still do not respond to the initial treatment or lose the efficacy within one year. Therefore, predicting which patients will respond to a specific treatment is an important challenge. ### Research Objectives 1. **Primary Scientific Objectives**: - Identify and validate a prediction model for predicting the clinical response or non - response of IBD patients within 14 weeks after receiving advanced therapies. - Build a model by combining gut microbiome, human genome, blood and gut single - cell transcriptome data, and detailed clinical data. 2. **Secondary Scientific Objectives**: - Determine the relationship between the baseline gut microbiome and clinical response and remission at 14 weeks. - Investigate the relationship between changes in the microbiome at baseline or after treatment and secondary clinical outcomes (such as clinical response and remission at 54 weeks, loss of response, etc.). 3. **Exploratory Scientific Objectives**: - Test the relationship between microbial metabolites in feces or plasma, human genetics, and single - cell transcriptome data and the primary and secondary objectives. - Study the effect of diet on the gut microbiome and treatment response. - Explore the role of host - genetic - gut - microbiome - metabolome interactions in the pathogenesis of IBD and treatment response. ### Research Design This research is a prospective, multi - center, observational cohort study. It is planned to recruit 1,325 IBD patients, including approximately 762 CD patients and 563 UC patients. Participants will provide fecal and blood samples at baseline, week 14, and week 54, and complete questionnaires. In addition, a nested sub - cohort (CD - metaRESPONSE) will conduct more detailed metabolome analysis and dietary assessment on 300 CD patients. ### Expected Outcomes Through this research, researchers hope to develop a prediction tool based on multi - omics data to help doctors select the most appropriate treatment method for each patient, thereby improving the treatment effect and reducing unnecessary drug side effects and economic burdens.